ESSEX INVESTMENT MANAGEMENT CO LLC - CRISPR THERAPEUTICS AG ownership

CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 439 filers reported holding CRISPR THERAPEUTICS AG in Q3 2022. The put-call ratio across all filers is 0.94 and the average weighting 0.2%.

Quarter-by-quarter ownership
ESSEX INVESTMENT MANAGEMENT CO LLC ownership history of CRISPR THERAPEUTICS AG
ValueSharesWeighting
Q3 2023$12,074
-19.1%
2660.0%0.00%0.0%
Q2 2023$14,933
-31.4%
266
-44.7%
0.00%
-33.3%
Q1 2023$21,756
+108680.0%
4810.0%0.00%0.0%
Q4 2022$20
-100.0%
481
-97.4%
0.00%
-98.4%
Q3 2022$1,188,000
+56.3%
18,182
+45.3%
0.19%
+54.5%
Q2 2022$760,000
-60.7%
12,514
-59.4%
0.12%
-49.0%
Q1 2022$1,934,000
-22.3%
30,811
-6.1%
0.24%
-15.4%
Q4 2021$2,488,000
-34.6%
32,828
-3.4%
0.28%
-39.0%
Q3 2021$3,803,000
-30.6%
33,974
+0.4%
0.47%
-26.7%
Q2 2021$5,478,000
+26.5%
33,836
-4.8%
0.64%
+20.6%
Q1 2021$4,331,000
+23.4%
35,540
-15.3%
0.53%
+5.2%
Q3 2020$3,510,000
+13.7%
41,966
-0.1%
0.50%
-0.8%
Q2 2020$3,088,000
+41.7%
42,026
-18.2%
0.51%
+14.7%
Q1 2020$2,179,000
-57.1%
51,371
-38.4%
0.44%
-29.4%
Q4 2019$5,082,000
+57.3%
83,448
+5.9%
0.62%
+34.1%
Q3 2019$3,231,000
-19.9%
78,819
-7.9%
0.47%
-15.7%
Q2 2019$4,032,000
+67.6%
85,599
+109.1%
0.55%
+83.7%
Q2 2018$2,406,000
+141.6%
40,939
+87.9%
0.30%
+129.8%
Q1 2018$996,000
-16.9%
21,790
-57.3%
0.13%
-17.1%
Q4 2017$1,199,00051,0800.16%
Other shareholders
CRISPR THERAPEUTICS AG shareholders Q3 2022
NameSharesValueWeighting ↓
Versant Venture Management, LLC 498,558$31,294,00031.24%
NEA Management Company, LLC 1,590,002$365,593,00010.56%
Ariose Capital Management Ltd 37,900$2,379,0009.30%
ARK Investment Management 9,404,071$590,294,0002.46%
NIA IMPACT ADVISORS, LLC 80,082$5,027,0002.44%
Nikko Asset Management Americas, Inc. 4,619,747$291,044,0002.14%
PLUSTICK MANAGEMENT LLC 50,000$3,139,0001.98%
Integral Health Asset Management, LLC 120,000$7,532,0001.96%
Valiant Capital Management, L.P. 240,683$15,108,0001.73%
Deuterium Capital Management, LLC 18,000$1,130,0001.45%
View complete list of CRISPR THERAPEUTICS AG shareholders